Tranexamic acid controlled-release

Drug Profile

Tranexamic acid controlled-release

Alternative Names: Lysteda; Tranexamic acid SR; Tranexamic acid sustained-release; XP-12B

Latest Information Update: 04 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xanodyne Pharmaceuticals
  • Class Antifibrinolytics; Antihaemorrhagics; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Menorrhagia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Jan 2013 Generic equivalent approved in USA for Menorrhagia
  • 07 Oct 2010 Efficacy and safety data from a phase III trial (NCT003863080) in Menorrhagia released by Ferring Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top